Glaucoma News and Research

Latest Glaucoma News and Research

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

Save money wih generics

Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.

10 Dec 2008

Cases of major eye disease projected to increase among diabetics

Based on projected increases in the prevalence of diabetes, the number of people with diabetes-related retinal disease, with glaucoma and with cataracts is estimated to increase significantly by 2050, according to a report in the December issue of Archives of Ophthalmology.

8 Dec 2008

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.

30 Nov 2008

Surgical options for retinal detachment

Retinal detachment, a condition that afflicts about 10,000 Americans each year, puts an individual at risk for vision loss or blindness.

26 Nov 2008

Sleep disorders linked to eye disease

If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue.

11 Nov 2008

Sleep disorder linked to eye disease

Research has already suggested that sleep problems can cause more than just tiredness - they have been linked to cardiovascular disease, cerebrovascular disease and metabolic disorders, and are also thought to raise the risk of obesity and diabetes.

10 Nov 2008

Latest glaucoma research

Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.

10 Nov 2008

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Pfizer Inc has announced that the U.S. Food and Drug Administration (FDA) approved Toviaz (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.

2 Nov 2008

Eye pressure spikes and glaucoma

A new Australian study has found some surprising factors which contribute to glaucoma and other pressure-related eye diseases.

29 Oct 2008

Gene find sheds light on motor neuron diseases like amyotrophic lateral sclerosis

Scientists have identified a gene in mice that plays a central role in the proper development of one of the nerve cells that goes bad in amyotrophic lateral sclerosis, or Lou Gehrig's disease, and some other diseases that affect our motor neurons.

22 Oct 2008

Diabetics more likely to lose their vision

Experts in the United States have found that vision loss is more common in people with diabetes than those without the disease.

14 Oct 2008

Visual impairment more common in people with diabetes

Visual impairment appears to be more common in people with diabetes than in those without the disease, according to a report in the October issue of Archives of Ophthalmology.

13 Oct 2008

No blood needed thanks to non-invasive blood monitoring device

A non-invasive blood monitoring device that removes the need to draw blood to monitor patients has won the 2008 Kerrin Rennie Award for Excellence in Medical Technology. The award was presented to Masimo Corporation on 24 September at the Medical Technology Association of Australia (MTAA) dinner in Sydney.

28 Sep 2008

SOLX receives FDA clearance for new glaucoma laser

SOLX, Inc. has announced U.S. Food and Drug (FDA) 510(k) clearance for the SOLX 790 to perform Titanium:Sapphire laser trabeculoplasty (TLT).

21 Sep 2008

Receptor activation protects retina from diabetes destruction

A drug known for it pain-relieving power and believed to stimulate memory appears to prevent this retinal damage that leads to vision loss, researchers say.

9 Sep 2008

Medication slows progression of myopia in children

Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).

26 Aug 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Children who spend more time outdoors are less likely to develop short-sightedness

"The results of this study are consistent with an American study which found that outdoor sport was protective, however our study shows that the crucial feature is being outdoors irrespective of the activity you are doing."

11 Aug 2008

Laser therapy more effective than corticosteroids in long term treatment of diabetic macular edema

A promising new drug therapy used to treat abnormal swelling in the eye - a condition called diabetic macular edema - proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the National Institutes of Health (NIH).

29 Jul 2008